Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | NPC1 | O15118 | 4/20 | 0.57 |
| ▸ | RAB9A | P51151 | 4/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.54 |
| ▸ | PRKX | P51817 | 1/20 | 0.54 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.54 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6354409 | 0.83 | NPC1 (0.56) | ALDH1A1NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL15876088 | 0.83 | S1PR1 (0.60) | ALDH1A1NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL6357846 | 0.83 | SGMS2 (0.61) | ALDH1A1NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL6355280 | 0.82 | LMNA (0.55) | ALDH1A1SMN1; SMN2KMT2AMAPK8HTT | |
| SCHEMBL6356674 | 0.81 | KMT2A (0.57) | ALDH1A1NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL6356702 | 0.80 | MAPK8 (0.57) | ALDH1A1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL6356922 | 0.80 | LMNA (0.57) | ALDH1A1NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL6355643 | 0.80 | HPGD (0.54) | ALDH1A1NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL6355252 | 0.78 | SGMS2 (0.61) | ALDH1A1NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL6356112 | 0.78 | TSHR (0.58) | ALDH1A1NPC1RAB9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050009812-A1 | Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-01-13 | — | — | US | claimed |
| EP-1438973-A1 | REMEDIES FOR STRESS DISEASES COMPRISING MITOCHONDRIAL BENZODIAZEPINE RECEPTOR ANTAGONISTS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-07-21 | — | — | EP | claimed |
| US-20050009812-A1 | Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-01-13 | — | — | US | disclosed |
| EP-1438973-A1 | REMEDIES FOR STRESS DISEASES COMPRISING MITOCHONDRIAL BENZODIAZEPINE RECEPTOR ANTAGONISTS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-07-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009812-A1 | Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists | TFAM, CYP11B2, CYP11B1 | ALDH1A1 1194/4885NPC1 719/4885RAB9A 2578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.